Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
Histopathology|September 7, 2016
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare targetChristina I Selinger, Bob T Li, Nick Pavlakis, et al.
BMJ Open|September 14, 2018
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)Antony J Mersiades, Annette Tognela, Paul S Haber, et al.
BMC Cancer|November 8, 2024
DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocolCassandra White, Hannah Wardill, Christine Paul, et al.
Nature Communications|February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATELavinia Tan, Chris Brown, Antony Mersiades, et al.
The American Journal of Surgical Pathology|June 26, 2013
BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndromeChristopher W Toon, Michael D Walsh, Angela Chou, et al.
JAMA Network Open|February 21, 2022
Effect of Cancer Pain Guideline Implementation on Pain Outcomes Among Adult Outpatients With Cancer-Related Pain: A Stepped Wedge Cluster Randomized TrialMelanie R Lovell, Jane L Phillips, Tim Luckett, et al.
JTO Clinical and Research Reports|September 30, 2021
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian PopulationTamkin Ahmadzada, Wendy A Cooper, Mikaela Holmes, et al.
The Lancet. Oncology|November 22, 2012
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialAimery de Gramont, Eric Van Cutsem, Hans-Joachim Schmoll, et al.
Nature Reviews. Drug Discovery|April 2, 2011
Managing the challenge of chemically reactive metabolites in drug developmentB Kevin Park, Alan Boobis, Stephen Clarke, et al.
JTO Clinical and Research Reports|October 24, 2022
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 StudyQuincy Chu, Natasha B Leighl, Veerle Surmont, et al.
Pageof 20